Clinical Trial Update: Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial sponsored by Scripps Health evaluated low-dose vemurafenib with rituximab for hairy cell leukemia. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Rituxan (rituximab)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Scripps Health | Conditions: Hairy Cell Leukemia | Phase 2 | Status: COMPLETED